Cannabidiol as a therapeutic modality for covid-19

Patent metadata

Field	Value
Publication number	US-2023338396-A1
Application number	US-202117998790-A
Country	US
Kind code	A1
Filing date	May 14, 2021
Priority date	May 14, 2020
Publication date	Oct 26, 2023
Grant date	—

Abstract

Compositions and methods for treating or reducing symptoms of COVID-19 are provided herein. An exemplary method includes administering to the subject an effective amount of cannabidiol to reduce acute respiratory distress syndrome caused by COVID-19.

First claim

We claim:

1 . A method of reducing inflammatory symptoms of COVID-19 in a subject in need thereof comprising administering to the subject an amount of cannabidiol effective to reduce inflammation in the subject.

2 . The method of claim 1 , wherein the subject has Acute respiratory distress syndrome wherein administration of the cannabidiol reduces pulmonary inflammation in the subject.

3 . The method of claim 2 , wherein the cannabidiol reduces the level of inflammatory cytokines in the subject compared to cytokine levels prior to administration of cannabidiol.

4 . The method of claim 3 , wherein the inflammatory cytokines are selected from the group consisting of IL-6, IFNγ and TNFα.

5 . The method of claim 3 , wherein the inflammatory cytokines are in the lung or airways.

6 . The method of claim 2 , wherein the cannabidiol treatment reduces inflammatory damage to the lungs.

7 . The method of claim 2 , wherein the cannabidiol treatment improves the functional capacity of the lungs.

8 . The method of claim 2 , wherein the acute respiratory distress syndrome is caused by coronavirus infection.

9 . A pharmaceutical composition comprising an effective amount of a cannabinoid to reduce inflammation in a subject in need thereof.

10 . The pharmaceutical composition of claim 8 , wherein the composition is formulated for pulmonary, nasal, or aerosol administration.

11 . (canceled)

12 . (canceled)

13 . The pharmaceutical composition of claim 8 , wherein the cannabinoid is cannabidiol.

14 . The pharmaceutical composition of claim 8 , wherein the cannabinoid is selected from the group consisting of tetrahydrocannabinols (THC), delta-9-tetrahydrocannabinol and delta-8-tetrahydrocannabinol, cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabidivarin (CBDV) and cannabichromene (CBC), cannabicyclol (CBL), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), arachidonoylethanolamine (AEA), 2-arachidonoylglycerol (2-AG), 2-arachidonyl glyceryl ether (noladin ether), N-arachidonoyl dopamine (NADA), virodhamine (OAE) lysophosphatidylinositol (LPI), nabilone, rimonabant, JWH-073, CP-55940, dimethylheptylpyran, HU-210, HU-331, SR144528, WIN 55,212-2, JWH-133, levonantradol, and AM-2201 and combinations thereof.

15 . A method of reducing pulmonary inflammation in a subject in need thereof comprising administering to the subject an effective amount of a cannabinoid to reduce the pulmonary inflammation.

16 . The method of claim 15 , wherein the cannabinoid is cannabidiol.

17 . The method of claim 15 , wherein the cannabinoid is selected from the group consisting of tetrahydrocannabinols (THC), preferably delta-9-tetrahydrocannabinol and delta-8-tetrahydrocannabinol, cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabidivarin (CBDV) and cannabichromene (CBC), cannabicyclol (CBL), cannabichromevarin (CBCV), cannabigerovarin (CBGV) and cannabigerol monomethyl ether (CBGM), arachidonoylethanolamine (AEA), 2-arachidonoylglycerol (2-AG), 2-arachidonyl glyceryl ether (noladin ether), N-arachidonoyl dopamine (NADA), virodhamine (OAE) lysophosphatidylinositol (LPI), nabilone, rimonabant, JWH-073, CP-55940, dimethylheptylpyran, HU-210, HU-331, SR144528, WIN 55,212-2, JWH-133, levonantradol, and AM-2201 and combinations thereof.

18 . The method of claim 15 , wherein the subject is infected with a coronavirus.

19 . The method of claim 18 , wherein the coronavirus is SARS-CoV-2.

20 . The method of claim 15 , wherein the subject has ARDS.

21 . The method of claim 15 , wherein administering an effective amount of a cannabinoid futher reduces or treats a cytokine storm in a subject in need thereof.

22 . (canceled)

23 . (canceled)

24 . (canceled)

25 . (canceled)

Assignees

• Univ Res Inst Inc Augusta

Inventors

• Baban Babak
• Dhandapani Krishnan M
• Yu Jack

Classifications

• A61K36/3482

  Cannabis · CPC title

• A61K31/658 Primary

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12 Primary

  Antivirals · CPC title